---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-296710"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2026-07-07T01:55:41+00:00"
generated_at: "2026-07-07T10:05:26.855536+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vertex to acquire Crinetics Pharmaceuticals for $85.00 per share in cash; expected close Q3 2026

## Summary
- Vertex to acquire Crinetics for $85.00 per share in cash; expected to close in Q3 2026.
- $4.5B bridge loan facility from Bank of America and Morgan Stanley backs the deal; no financing condition.
- Crinetics stockholders must approve; HSR and foreign regulatory clearances required; termination fee of $350M.
- Vertex expects deal to accelerate revenue growth, with potential >$5B annual revenue; accretive to non-GAAP op income by 2029.
- Crinetics' pipeline includes PALSONIFY (acromegaly) and atumelnant (CAH); Vertex sees significant commercial potential.

## SEC filing metadata
- accession: 0001193125-26-296710
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2026-07-07T01:55:41+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/0001193125-26-296710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/d113650d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-296710
- JSON: https://secwatch.observer/filing/0001193125-26-296710.json
- Plain text: https://secwatch.observer/filing/0001193125-26-296710.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.